Meagan O'BrienDirector of Early Clinical Development and Clinical Experimental Sciences at Regeneron Pharmaceuticals, UK
Meagan O’Brien is a Director of Early Clinical Development and Clinical Experimental Sciences at Regeneron Pharmaceuticals. Dr. O’Brien received her medical degree from Harvard Medical School and completed medical residency and a fellowship in infectious diseases in New York City at Columbia Presbyterian and New York University Medical Schools. Dr. O’Brien’s NIHsponsored academic research focused on innate immune dysregulation by chronic viral infections and chronic inflammation in HIV infection. Dr. O’Brien joined Regeneron in 2017 to work in Early Clinical development, with a focus on allergy and immunology.